QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab AutomationBusiness Wire • 04/15/25
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS OutlookBusiness Wire • 04/06/25
QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance EffortsBusiness Wire • 04/01/25
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal PanelZacks Investment Research • 03/07/25
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolioBusiness Wire • 03/06/25
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testingBusiness Wire • 03/03/25
2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62%The Motley Fool • 02/23/25
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific RegionBusiness Wire • 02/13/25
QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patentBusiness Wire • 02/04/25
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 MillionBusiness Wire • 01/16/25
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share RepurchaseBusiness Wire • 01/12/25